Vimarsana
Biggest News Aggregation in the World

Vanda Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vanda Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vanda Pharmaceutical Today - Breaking & Trending Today

Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer - Vimarsana News

Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer

Investment firm Shareholder Capital sent a letter to drugmaker Vanda Pharmaceuticals' board on Thursday asking it to reconsider Future Pak's takeover offer. On April 17, Vanda rejected...

How Trump Could Reshape Healthcare; E. Coli Alert; Does Doctor's Gender Matter? - Vimarsana News

How Trump Could Reshape Healthcare; E. Coli Alert; Does Doctor's Gender Matter?

Health news and commentary gathered by <em>MedPage Today</em> staff

US FDA approves Vanda's drug for treatment of bipolar disorder | WSAU News/Talk 550 AM &#xB7; 99.9 FM - Vimarsana News

US FDA approves Vanda's drug for treatment of bipolar disorder | WSAU News/Talk 550 AM &#xB7; 99.9 FM

(Reuters) -The U.S. FDA approved Vanda Pharmaceuticals' drug to treat manic and mixed episodes associated with a type of bipolar disorder, the company said on Tuesday, marking the second approval for the treatment. Shares of the Washington, D.C.-based ...

Source: wsau.com
FDA Approves Iloperidone (Fanapt) for Acute Treatment of Bipolar I Disorder - Vimarsana News

FDA Approves Iloperidone (Fanapt) for Acute Treatment of Bipolar I Disorder

The FDA approved iloperidone for acute treatment of bipolar I disorder on April 02, 2024, according to Vanda Pharmaceuticals.

US FDA approves Vanda's drug for treatment of bipolar disorder - Vimarsana News

US FDA approves Vanda's drug for treatment of bipolar disorder

The U.S. FDA approved Vanda Pharmaceuticals' drug to treat manic and mixed episodes associated with a type of bipolar disorder, the company said on Tuesday, marking the second approval for the...